Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
Andreas Jahn(University of Washington), Patrick Schöffski(KU Leuven), Martin Hoffmann(Klinikum Ludwigshafen), Ali Aldaoud(Klinikum Braunschweig), Hartmut Link(Medizinische Hochschule Hannover), Burkhard Otremba(Saarland University), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Ulrich Kaiser(University of Applied Sciences Landshut), Silke Steinbach(Krankenhaus vom Roten Kreuz), G. Huebner(Westpfalz Klinikum), M Menges(Klinikum Ludwigshafen), H. Bernhard(TUM Klinikum), C.-H. Köhne(Klinikum Oldenburg), Albrecht Kretzschmar(Roche (Switzerland)), Christoph Burkart(aTyr Pharma (United States)), Michael Stahl(Kliniken Essen-Mitte), Gunnar Folprecht, Frank Kullmann(Klinikum Weiden)
Cited by 87
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k